Status:
TERMINATED
Identifying Mechanisms of Resistance to mTOR Inhibitors in Cancer
Lead Sponsor:
Dartmouth-Hitchcock Medical Center
Conditions:
Cancer
Eligibility:
All Genders
18-100 years
Brief Summary
mTOR kinase is part of the mTORC1 complex that promotes cap-dependent protein translation, and part of the mTORC2 complex that activates AKT. Everolimus (Afinitor) is an allosteric inhibitor of mTOR t...
Eligibility Criteria
Inclusion
- Treatment with everolimus (as a single-agent or in combination) for any malignancy for ≥3 months.
- A- Patients who are scheduled to undergo a clinically indicated tumor biopsy (as standard of care, or as part of another study) within 5 years following cancer progression on everolimus are eligible.
- B- Patients who already had such a biopsy procedure performed are eligible. Tumors biopsied shortly after progression on everolimus are strongly preferred.
- Excess tumor tissue from biopsy must be available for molecular analysis. This will include tumor tissue sufficient to make ≥5 five-micron sections; more tumor tissue is preferred.
- Patients currently seen at Dartmouth-Hitchcock Medical Center must be capable and willing to provide informed written consent for study participation. Patients who are no longer seen at DHMC will not be consented for use of archived tissues and data.
- For patients currently seen at Dartmouth-Hitchcock Medical Center, patients must be willing to provide an extra 10-20 mL of blood during a routine, clinically indicated blood draw procedure.
Exclusion
- none
Key Trial Info
Start Date :
March 1 2015
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 1 2016
Estimated Enrollment :
2 Patients enrolled
Trial Details
Trial ID
NCT02306135
Start Date
March 1 2015
End Date
March 1 2016
Last Update
April 27 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire, United States, 03756